Press Releases Cybin Inc.

Equities

HELP

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-13 pm EDT			5-day change	1st Jan Change
4.640 ^USD	-9.55%		-11.62%	-43.28%

Mar. 12	Helus Pharma Announces Appointment of Jill Conwell as Chief People Officer, Effective on March 12, 2026	CI
Mar. 06	Cybin Inc. - Special Call

Press Releases

Mar. 12	Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer	GL
Mar. 09	CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions	AQ
Mar. 05	Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion	AQ
Mar. 05	Cybin : Helus Pharma Announces Positive Phase 2 Data For Its Novel Serotonergic Agonist in Generalized Anxiety Disorder (GAD)	PU
Mar. 05	Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder	GL
Feb. 24	Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee	GL
Feb. 17	Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder	GL
Feb. 13	HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights	GL
Feb. 10	Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution	GL
Jan. 06	Cybin : Corporate Presentation January 2026	PU
Jan. 05	HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq	BU
Dec. 30	Cybin Initiates At-The-Market Equity Program of up to US$100 Million	BU
Dec. 19	Cybin : to Transfer U.S. Stock Exchange Listing to Nasdaq	PU
Dec. 18	Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq	BU
Nov. 13	Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights	BU
Nov. 12	Cybin to Participate in the Jefferies Global Healthcare Conference in London	BU
Nov. 06	Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025	BU
Nov. 05	Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference	BU
Nov. 03	Cybin to Participate at the 2025 Milken Institute Future of Health Summit	BU
25-10-31	Cybin Announces Closing of $175 Million Registered Direct Offering	BU
25-10-28	Canadian Investment Regulatory Organization Trade Resumption - CYBN	AQ
25-10-28	Canadian Investment Regulatory Organization Trading Halt - CYBN	AQ
25-10-28	Cybin Announces $175 Million Registered Direct Offering	BU
25-09-23	Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones	BU
25-09-11	Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit	BU